Literature DB >> 1083376

Restoration of delayed hypersensitivity to sheep erythrocytes by thymosin treatment of T-cell-depleted mice.

F M Collins, N E Morrison.   

Abstract

Calf thymosin was injected subcutaneously in daily doses of 0.1 to 3 mg for 12 to 15 days into adult thymectomized, irradiated, bone marrow-reconstituted (THXB) mice. Thymosin partially restored the ability of the T-cell-depleted host to develop delayed-type hypersensitivity to sheep erythrocytes. The degree of restoration varied from 50 to 75% of control values. Thymosin treatment of normal mice potentiated the footpad responsiveness to sheep erythrocytes by as much as 50% over that of untreated controls. The optimum dosage of thymosin seemed to be in the 200- to 500-mug range, and multiple injections were essential for a significant response. Tweleve daily injections of 100 to 500 mug of thymosin restored T-cell reactivity to the THXB mouse, but the responsiveness decayed relatively rapidly once the treatment was stopped. The restoration of immune responsiveness to sheep erythrocytes in T-cell-depleted mice provides a convenient means of demonstrating activity in thymosin preparations in vivo.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1083376      PMCID: PMC420647          DOI: 10.1128/iai.13.2.564-568.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  19 in total

1.  Purification and properties of bovine thymosin.

Authors:  J A Hooper; M C McDaniel; G B Thurman; G H Cohen; R S Schulof; A L Goldstein
Journal:  Ann N Y Acad Sci       Date:  1975-02-28       Impact factor: 5.691

2.  Influence of dose and route of antigen injection on the immunological induction of T cells.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-03-01       Impact factor: 14.307

3.  On the mode of action of thymosin.

Authors:  E M Lance; S C Gillette; A L Goldstein; A White; M M Zatz
Journal:  Cell Immunol       Date:  1973-01       Impact factor: 4.868

4.  Importance of thymus-derived lymphocytes in cell-mediated immunity to infection.

Authors:  R J North
Journal:  Cell Immunol       Date:  1973-04       Impact factor: 4.868

5.  Immunopotentiation with BCG. II. Modulation of the response to sheep red blood cells.

Authors:  T E Miller; G B Mackaness; P H Lagrange
Journal:  J Natl Cancer Inst       Date:  1973-11       Impact factor: 13.506

Review 6.  Resistance to intracellular infection.

Authors:  G B Mackaness
Journal:  J Infect Dis       Date:  1971-04       Impact factor: 5.226

Review 7.  T cell response to viral and bacterial infection.

Authors:  R V Blanden
Journal:  Transplant Rev       Date:  1974

Review 8.  The thymus and the cellular basis of immunity.

Authors:  A J Davies
Journal:  Transplant Rev       Date:  1969

9.  Effect of thymic factors on the differentiation of human marrow cells into T-lympnocytes in vitro in normals and patients with immunodeficiencies.

Authors:  J L Touraine; F Touraine; G S Incefy; R A Good
Journal:  Ann N Y Acad Sci       Date:  1975-02-28       Impact factor: 5.691

10.  Potentiation of T-cell-mediated immunity by selective suppression of antibody formation with cyclophosphamide.

Authors:  P H Lagrange; G B Mackaness; T E Miller
Journal:  J Exp Med       Date:  1974-06-01       Impact factor: 14.307

View more
  4 in total

1.  Restoration of T-cell responsiveness by thymosin: development of antituberculous resistance in BCG-infected animals.

Authors:  N E Morrison; F M Collins
Journal:  Infect Immun       Date:  1976-02       Impact factor: 3.441

2.  Thymus hormones.

Authors: 
Journal:  Br Med J       Date:  1977-06-18

3.  Restoration of T-cell responsiveness by thymosin: expression of anti-tuberculous immunity in mouse lungs.

Authors:  F M Collins; N E Morrison
Journal:  Infect Immun       Date:  1979-02       Impact factor: 3.441

4.  The specificity of suppressor T cells induced by chronic Mycobacterium avium infection in mice.

Authors:  S R Watson; F M Collins
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.